Skip to content

Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock

Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02600312
Acronym
oXiris
Enrollment
16
Registered
2015-11-09
Start date
2015-10-31
Completion date
2018-01-31
Last updated
2019-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Septic Shock

Brief summary

The Oxiris® filter is a registered product for CRRT already safely used in routine care. In in vitro experiments, the Oxiris® filter has been demonstrated to adsorb endotoxin and cytokines. Compared to conventional filters this may be advantageous in patients with severe sepsis but neither decreased levels of endotoxin and cytokines nor an improved outcome has been demonstrated with clinical use. But there are so far little clinical data on the oXiris® filter on humans. The oXiris® filter will be investigated in a double blind randomized crossover setting against a traditional filter (ST150). Either filter will be used for 24 hours after which it will be changed to the opposite filter for another 24 hours. Arterial blood samples will be drawn at start and then 1, 3, 8, 16 and 24 hours after the start of each filter, and analyzed for endotoxin (EAA assay), TNF-α, IL-1β, IL-6 and IL-10 (ELISA) levels. Standard blood tests will be analyzed simultaneously. Data concerning mode and settings of CRRT, heart rate, blood pressure, medication, data concerning ventilatory support and pathogen will be registered. Primary endpoint: Levels of endotoxin and cytokines will be compared using Student's paired t-test on AUC values for each 24-hour period.

Interventions

DEVICEoXiris

oXiris CRRT filter which adsorbs cytokines, toxins.

Sponsors

Skane University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients admitted to intensive care unit (ICU) of age \>18 years with decision based on the clinical situation of the patient taken by the physician in charge that continuous renal replacement therapy will be started. 2. Vasoconstrictor and volume dependent septic shock with known Gram-negative infectious agent in blood culture. 3. Vasoconstrictor and volume dependent septic shock suspected to be caused by a Gram-negative agent and with positive plasma endotoxin test.

Exclusion criteria

1. Infected with Hepatitis B or C or HIV. 2. Dependence on dialysis treatment before the actual ICU episode.

Design outcomes

Primary

MeasureTime frameDescription
endotoxin level in bloodchange from baseline to 48 hoursDescribes the load of toxins from the septic state. Higher load means increased impact from the infectious state mediated through the septic shock. Expected mean differences in endotoxin levels including standard deviation is based on data from a previous study on extracorporeal endotoxin removal in sepsis patients (reference 1).

Secondary

MeasureTime frameDescription
mean blood pressurehourly up to 48 hoursAdditional parameter that describes the clinical impact from the septic state.
TNF-α level in bloodchange from baseline to 48 hoursAdditional parameter that describes the load from the septic shock.
IL-6 level in bloodchange from baseline to 48 hoursAdditional parameter that describes the load from the septic shock.
IL-10change from baseline to 48 hoursAdditional parameter that describes the load from the septic shock.
IL-1β level in bloodchange from baseline to 48 hoursAdditional parameter that describes the load from the septic shock.

Other

MeasureTime frameDescription
level of vasoconstrictive infusionhourly up to 48 hoursNeed of vasoconstrictor because of shock, higher degree of shock means increased requirement of vasoconstrictor infusion.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026